CLDN4 and lung adenocarcinoma: The current study’s findings were consistent with Patel et al., who evaluated the expression of Claudin-4 in 58 pleural effusion cell block sections, comprising 10 benign effusions with RMCs, 8 instances of MPM, 40 lung adenocarcinomas.